Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

This article explains how regulators assess the Pharmacovigilance System Master File during inspections, where governance gaps create audit findings, and why clear accountability, traceability, and inspection readiness determine long-term regulatory confidence.
An inspection-driven overview explaining how regulators assess benefit–risk narratives in PBRERs, where governance gaps trigger repeat findings, and how structured oversight across reporting cycles strengthens compliance and regulatory confidence in pharmacovigilance systems.
This article explains how regulators assess DSURs during clinical development, focusing on safety governance, benefit–risk assessment, and data consistency across trials. It highlights common inspection findings and shows how structured oversight reduces regulatory risk and inspection escalation.
This article explains how regulators assess the Pharmacovigilance System Master File during inspections, where governance gaps create audit findings, and why clear accountability, traceability, and inspection readiness determine long-term regulatory confidence.
This article explains how PSURs support regulatory assessment through structured benefit–risk evaluation, safety data integration, and inspection readiness, helping organizations maintain consistent safety reasoning and meet evolving regulatory expectations across post-marketing reporting cycles.
This article examines how artificial intelligence supports drug safety activities, from adverse event detection to safety data analytics, while regulatory oversight, human decision authority, and clear AI governance frameworks remain central to compliant pharmacovigilance operations.
This article explores pharmacovigilance as a structured safety governance system that integrates safety data, regulatory oversight, and decision accountability. It explains how governance-driven models improve inspection readiness, strengthen regulatory trust, and support consistent post-marketing safety decisions across the product lifecycle.
Purified Water systems seldom fail due to equipment; they decline silently through biofilm formation, flawed loop design, and absent microbial trending. In a project at a South American pharmaceutical company we found significant microbial deviations with no investigations or trending
During a PW validation for a South American pharma manufacturer, the team found solid equipment but no meaningful risk assessment. Parameters were adopted without justification and worst-case conditions were not challenged. Validations were paperwork-only, leading to rework, inspection findings, delays,
A Pharma company’s purified water (PW) system remained officially validated, but after three years without reassessment or maintenance it drifted out of its validated state. Lack of periodic requalification, preventive maintenance, and trending led to unpredictable performance and increased risk